Fill in the form to have a Dassault Systèmes expert contact you to answer your questions and discuss any of your needs.
Patrick JOHNSON, Dassault Systèmes
Basic cancer research has made truly extraordinary strides forward over the past half century and in an ideal world, most of the common human cancers should have been reduced to curable diseases by now. Indeed, such a course of events describes the dramatic reductions in various types of cardiovascular treatments, but cancer has lagged behind. We now realize that cancer is a collection of diseases of extraordinary variability from individual to individual and that cancers that initially have responded to dramatic advances in treatment that, more often than not, re-emerge in treatment-resistant forms. The cells that drive tumor formation are now known to be almost complex beyond measure, and the ability to predict patient responses in the oncology clinic continues to be limited. For the moment, the development of molecular therapies has hit a brick wall with the great hope being placed at present in future forms of immunotherapy, itself a complex field with a not totally predictable future.
Dr. Rose LOUGHLIN, Moderna Therapeutics
How Moderna is utilizing advanced technology to make better mRNA medicines.
Lucas NIVON, Cyrus Biotechnology
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. In protein biochemistry these are the “AIFold” models such as AlphaFold2, RoseTTAFold, and OpenFold.
OpenFold is a non-profit AI research and development consortium developing open-source software tools for biology and drug discovery. It outperforms previous models as well as physics-based systems at structure prediction. More recently protein design models such as MPNN and RFDiffusion out of David Baker’s lab and other groups have extended from prediction to design of novel proteins. Like in other fields of AI, these so-called “foundation models” are open source, and future innovation in the technology will be collaborative, with value creation inside companies and academia on unique, proprietary therapeutic or biotech assets and narrowly-framed large-scale biotech data around key value propositions such as proteins stability or solubility. We provide examples from Cyrus’s work in creating AI-enhanced variants of natural proteins as superior therapeutics, leveraging OpenFold and other open source tool
Dr. Yann COTTE, Nanolive
Harnessing AI-powered analytics from unprecedented label-free 3D live cell data has significant translational relevance for therapeutic innovation for humans. Advancements in imaging technologies, specifically label-free techniques, and computational techniques have enabled the generation of vast amounts of high-plex, real-time cellular data. Integrating artificial intelligence (AI) algorithms and analytics enables the effective processing and analysis of this data, leading to valuable insights into cellular behavior, disease mechanisms, and therapeutic responses. This transformative approach has the potential to revolutionize drug discovery, personalized medicine, and treatment optimization in humans. By leveraging AI-powered analytics on label-free 3D live cell data, researchers can accelerate the development of novel therapies from in vitro assays, thanks to dynamic & parallel analytics on mode-of-action derived from primary or ipsc cell-lines, and bring about meaningful advancements in translational medicine.
Dan ISAACS, Object Management Group
Digital twins are being recognized as providing value across virtually every industry.
This session will explore digital twin innovation and value across real-world use cases, including digital twins in health, industry, and sustainability. From using digital twins to model and predict the progression of diseases to developing personalized treatment plans, digital twins can further optimize production processes and reduce waste. The values of digital twins extend beyond health and industry. By incorporating sustainability and circular economy principles, such as carbon reporting and management for carbon credit generation of our rapidly depleting rain forests, digital twins can help us create a more sustainable future. As a critical enabler of digital transformation, learn how digital twins drive innovation and value in health, industry, and sustainability.
Olivier de WECK, MIT
The degree of complexity of today's products and systems is significantly higher than it was in the 20th century or earlier. This increased complexity, similar to what we see in highly evolved natural biological systems, yields higher levels of performance and potentially resilience. However, I will show that there are diminishing returns in further increasing complexity, because design effort increases super-linearly with complexity while approaching fundamental physical limits. In this talk I will postulate that Conservation of Complexity should be considered as the First Law of System Science, similar to conservation of energy in thermodynamics, or conservation of momentum in classical mechanics. I will show examples of design evolution for air-breathing engines, as well as digital printing systems to provide empirical evidence for this claim. In a nutshell, complexity should be explicitly quantified and tracked during the design process.
Dr. Shahriar SHAHRAMIAN, Bell Labs
The communication networks of today leverage a wide range of the electromagnetic spectrum. From microwaves to infrared light, human ingenuity harnesses the laws of physics to interconnect our species across the globe. Through joint communication and sensing, the 6G networks of tomorrow will bring an unprecedented level of complexity where user applications are aware of the network and our networks dynamically adapt to emerging applications.
Kent LARSON, MIT
Modeling strategies to dramatically reduce urban GHG emissions while simultaneously improving the residents' quality of life and economic opportunities.
Paloma GONZALEZ-ROJAS, Atacama Biomaterials
José Tomás DOMÍNGUEZ, Atacama Biomaterials
Exploring AI's role in shaping a sustainable bio economy, via Atacama's innovative green materials manufacturing tech.
Dr. Valeria La SAPONARA, University of California
We will showcase how nature in this case fungi and their root system (mycelium) as a key ingredient to develop novel material technologies for a more sustainable world. The potential applications of interdisciplinary research and innovation based on fungi are in Life Sciences, Manufacturing, Infrastructure, Food Science and Nutrition, Healthcare. Fungus-like mycelium have been found in fossils in 2.4 billion years basalt. Humans have been using them for food, medicines, tinder etc. for several thousands of years. Fungi for medicine and tinder have been found on "Iceman" Ötzi's body (dated around 3,000 BC). The world's largest living organism that we know of is a fungus occupying about 2,400 acres in Oregon. We are using fungi as fully biodegradable construction material and we use them to break down plastics, contaminants in construction materials, and serious environmental contaminants like DDT, PCBs, arsenic and radioactive soil in Chernobyl Red Forest. We are making vegan leather and vegan meat using fungi. We are competing with fungal pathogens to secure our food supply. It is estimated that only 6% of species of the Fungal Kingdom is known. Scientists are banding together for mapping and protecting the underground mycelial networks. Advancing knowledge of fungi and fungi-based materials are key catalysts for sustainable science and engineering, with considerable benefits for our environment.
Patrick JOHNSON, Dassault Systèmes
Professor William CHEN, Nanyang Technological University, Singapore
With the increasing pressure on food production to feed the growing world population, there has been a global effort in pushing for primary production. Considering the linear nature of the current food system (from farm to fork), new approaches in tech innovations can be designed and implemented to enhance its efficiency and unexpectedly synergize with the development of alternative foods. We in Singapore have demonstrated that innovations in upcycling food waste not only lead to food circular economy but also contribute to more sustainable future of alternative foods.
Dr. Anne PITKOWSKI, Bel Group
In a world where we are facing the scarcity of raw materials while observing population growth – it is essential to act to support the food transition. Alternative proteins are one of the promising solutions for the future – offering a functional nutritional source with low environmental impact.
At Bel, we explore all possible alternatives and technical solutions in order to serve our ambition: to offer healthy and sustainable food for all.
Pierre JAÏS, University of Bordeaux
Cardiac arrhythmias are frequent, affecting millions of people exposed to heart failure, stroke and sudden cardiac death. The vast majority of arrhythmia emanates from tissular changes (the substrate), that are amenable to increasingly more detailed description by imaging. AI based algorithms have been developed to generate digital twins of patient’s heart to guide catheter ablation of the most severe cardiac arrhythmias. This rupture innovation allows to reduce procedure time by over 50% while reducing recurrences by 20%. These twins will fast expand to sudden cardiac death risk prediction to help doctors deciding on the best preventive treatment to be applied to patients and, in a longer term, in the general population.
Dr. Alan ZAJARIAS, Washington University, St. Louis
Coronary and structural catheter based procedures have matured dramatically over the last decades. Equipment modification, procedural refinement and better patient selection have allowed expansion in patient of every risk strata. As indications increase, improving procedural safety and efficacy is imperative. Computer modeling is a reliable tool for the assessment of new technology and personalized risk assessment. Its use in the cardiac catheterization laboratory is increasing and hold promise. Successful modeling has the potential to improve patient outcomes, improve procedural efficiencies, decrease costs and potentially to decrease the evaluation time for new procedures.
Patrick JOHNSON, Dassault Systèmes